Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about TransMedics Group, Inc.
TransMedics Group, Inc. News
Apr 1, 2025 - accessnewswire.com
TMDX LAWSUIT ALERT: Levi & Korsinsky Notifies TransMedics Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Apr 1, 2025 - accessnewswire.com
Contact Levi & Korsinsky by April 15, 2025 Deadline to Join Class Action Against TransMedics Group, Inc. (TMDX)
Apr 1, 2025 - globenewswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Lawsuit – TMDX
Apr 1, 2025 - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in TransMedics Group, Inc of Class Action Lawsuit and Upcoming Deadlines - TMDX
TransMedics Group, Inc. Quantitative Score
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. Earnings & Revenue
TransMedics Group, Inc. Financials
Table Compare
Compare TMDX metrics with: | |||
|---|---|---|---|
Earnings & Growth | TMDX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | TMDX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | TMDX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | TMDX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
TransMedics Group, Inc. Income
TransMedics Group, Inc. Balance Sheet
TransMedics Group, Inc. Cash Flow
TransMedics Group, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
TransMedics Group, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
TransMedics Group, Inc. Executives
| Name | Role |
|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer & Director |
| Dr. Tamer I. Khayal M.D. | Chief Commercial Officer |
| Mr. Nicholas Corcoran | Senior Vice President of Supply Chain & Operations |
| Mr. Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary |
| Ms. Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer & Director | 1968 | 1.82M | |
| Dr. Tamer I. Khayal M.D. | Chief Commercial Officer | 1969 | 900.11K | |
| Mr. Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | Male | 1983 | 812.07K |
| Mr. Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary | Male | 561.67K | |
| Ms. Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs | Female | 1961 | 535.93K |
TransMedics Group, Inc. Insider Trades
| Date | 3 Mar |
| Name | Khayal Tamer I |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 2407 |
| Date | 25 Feb |
| Name | Hassanein Waleed H |
| Role | President & CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 59781 |
| Date | 25 Feb |
| Name | Hassanein Waleed H |
| Role | President & CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 90185 |
| Date | 24 Feb |
| Name | Hernandez Gerardo |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 3521 |
| Date | 24 Feb |
| Name | Hernandez Gerardo |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5299 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 3 Mar | Khayal Tamer I | Chief Commercial Officer | Disposed | S-Sale | 2407 |
| 25 Feb | Hassanein Waleed H | President & CEO | Acquired | A-Award | 59781 |
| 25 Feb | Hassanein Waleed H | President & CEO | Acquired | A-Award | 90185 |
| 24 Feb | Hernandez Gerardo | Chief Financial Officer | Acquired | A-Award | 3521 |
| 24 Feb | Hernandez Gerardo | Chief Financial Officer | Acquired | A-Award | 5299 |